Published: August 8, 2019

Introduction {#sec1}
============

During embryonic development, hematopoietic stem cells (HSCs) emerge from hemogenic endothelium in the ventral wall of the aorta-gonad-mesonephros (AGM) region ([@bib13], [@bib26], [@bib25]), and their specification is tightly orchestrated by temporal changes in the expression of master regulators during endothelial-to-hematopoietic transition (EHT). While animal models have been crucial in identifying several master regulators, such as GATA2, RUNX1, and TAL1 ([@bib48], [@bib64], [@bib66]), how these factors drive human HSC emergence during EHT remains poorly understood.

GATA2 belongs to an evolutionarily conserved family of zinc finger transcription factors comprising six members: GATA1 to GATA6 ([@bib38], [@bib39]). GATA2, together with GATA1 and GATA3, are categorized as "hematopoietic" GATA factors and regulate the development of diverse hematopoietic lineages ([@bib3], [@bib27], [@bib29], [@bib43]). The importance of GATA2 in HSC specification was first highlighted by gene targeting studies, because ablation of *Gata2* is embryonic lethal at embryonic day (E)10.5 due to the collapse of primitive and definitive hematopoiesis ([@bib18], [@bib35], [@bib60]). Notably, analysis of chimeric embryos generated with *Gata2*-null embryonic stem cells (ESCs) indicated that these cells failed to contribute to any hematopoietic lineage ([@bib59]). Likewise, mouse *Gata2*-null endothelial cells failed to produce HSCs because of impaired EHT ([@bib10], [@bib18], [@bib27], [@bib34]). A primary role of GATA2 in promoting EHT has been recently demonstrated in humans ([@bib20], [@bib28], [@bib68]).

In adult hematopoiesis, GATA2 is expressed at high levels in HSCs, early hematopoietic progenitors, and in erythroid/megakaryocyte lineages ([@bib62]). Recent studies showed that *GATA2* haploinsufficiency is associated with some familial cases of myelodysplastic syndrome, bone marrow failure, immunodeficiency, and MonoMAc syndrome ([@bib11], [@bib21], [@bib67]), further supporting its important role in HSCs. Conversely, enforced expression of *GATA2* in cord blood-derived HSCs confers increased quiescence, an important hallmark of HSCs ([@bib58]).

We sought to explore the role of GATA2 during human hematopoietic development by inducing *GATA2* expression in differentiating human induced pluripotent stem cells (hiPSCs) ([@bib57]). We show that *GATA2* induction during mesoderm patterning robustly promotes the generation of hemogenic endothelial progenitors (HEPs), and their further differentiation into hematopoietic progenitor cells (HPCs). Global transcriptome analysis and chromatin immunoprecipitation sequencing (ChIP-seq) combined with DNA massive sequencing revealed that GATA2 directly represses genes that promote cardiac cell fate differentiation and activates master hematopoietic regulators via direct and indirect mechanisms. Remarkably, *GATA2* knockout impaired hematopoietic development and enhanced cardiac potential of mesodermal progenitors.

Results {#sec2}
=======

GATA2 Promotes Robust Hematopoietic Differentiation {#sec2.1}
---------------------------------------------------

To analyze the impact of GATA2 in early human hematopoiesis, we first examined endogenous GATA2 expression in hiPSCs induced to form embryoid bodies (EBs) in serum-free medium with the successive addition of BMP4 (days 0--3), CHIR92001 (days 2--3), and hematopoietic cytokines (days 3--15) ([Figure 1](#fig1){ref-type="fig"}A). This protocol promotes mesoderm induction (days 2--3), specification of mesodermal cells to bipotential hemato-endothelial progenitors (CD31^+^CD34^+^CD43^-^CD45^−^; days 3--10) that can originate both endothelial and hematopoietic cells and could be considered equivalent to HEPs ([@bib1]), and further commitment of HEPs to definitive HPCs (CD34^+^CD43^+^CD45^+^; days 10--15) ([@bib19], [@bib55]). *GATA2* was initially expressed at day 2 ([Figure 1](#fig1){ref-type="fig"}B), at the onset of mesoderm formation marked by the expression of *T* and *MIXL1* ([Figure 1](#fig1){ref-type="fig"}C). Its expression then progressively increased along with the emergence of HEPs and HPCs, in parallel with the master hemogenic regulators *RUNX1* and *SCL* ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Early GATA2 Induction Enhances Hematopoietic Development from hiPSCs(A) hiPSC hematopoietic differentiation based on EB generation.(B) Time course of endogenous *GATA2*, *SCL/TAL1*, and *RUNX1* expression during EB development, normalized to *GAPDH*.(C) Time course of endogenous mesodermal marker expression (*BRACHYURY* and *MIXL1*) during EB development, normalized to *GAPDH*. In (B) and (C), data represent the mean ± SD of three independent experiments.(D) Representative flow cytometry analysis of HEPs (CD31^+^CD34^+^CD45^--^ and CD34^+^CD43^--^CD45^--^) and HPCs (CD34^+^CD45^+^ and CD43^+^CD45^+^) in EBs at days 10 and 15 in control and Dox-treated cells.(E) Quantitative summary of HEP and HPC analysis at days 10 and 15 of EB differentiation in control and Dox-treated cells.Data represent the mean ± SD of 10 independent experiments. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.

We next established transgenic hiPSCs in which the expression of transgenic *GATA2* could be temporally controlled by doxycycline (Dox) administration (hereafter termed iGATA2-hiPSCs) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Robust transgenic overexpression of *GATA2* was confirmed in four clones (CL6, CL9, CL201, CL204) derived from two independent iGATA2-hiPSC lines by western blotting after 2 days of Dox treatment ([Figure S1](#mmc1){ref-type="supplementary-material"}B). qRT-PCR analysis and *in vivo* functional assays showed that iGATA2-hiPSCs retained the expression of pluripotency markers and also the capacity to generate teratomas ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

Then, considering the expression of endogenous *GATA2*, we induced *GATA2* expression from day 2 to 7 in EBs generated from iGATA2-hiPSCs ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}D--S1G). Flow cytometry analysis showed that enforced expression of *GATA2* significantly enhanced the production of HEPs (∼2.5-fold increase of CD31^+^CD34^+^CD45^−^ cells and ∼2-fold increase of CD34^+^CD43^--^CD45^--^ cells) in EBs at day 10 ([Figures 1](#fig1){ref-type="fig"}D and 1E), and promoted the generation of HPCs (∼5-fold increase of CD34^+^CD43^+^CD45^+^ cells) at day 15 ([Figures 1](#fig1){ref-type="fig"}D and 1E).

We used colony-forming unit (CFU) assays to confirm that GATA2 overexpression promotes hematopoiesis from iGATA2-hiPSCs. Dox treatment (days 2--7) significantly increased the total number of hematopoietic CFCs in day 10 EBs ([Figure 2](#fig2){ref-type="fig"}A). Notably, CFU scoring revealed an enhancement in all types of hematopoietic colonies ([Figure 2](#fig2){ref-type="fig"}A), suggesting that GATA2 expression promotes hematopoietic commitment by inducing mesodermal specification to HEPs at very early stages.Figure 2GATA2 Induction Promotes Hemogenic Endothelium Transition(A) CFU potential of day 10 EB progenitors in control and Dox-treated cells. Colonies were counted from each group after 2 weeks of culture and scored for the following morphological subsets: burst-forming unit-erythroid (E); CFU-granulocyte, macrophage (GM); CFU-granulocyte, erythroid, macrophage, megakaryocyte (GEMM); CFU-granulocyte (CFU-G); and CFU-macrophage (CFU-M). Data represent the mean ± SD of the total number of colonies per 50,000 cells seeded of 6 independent experiments.(B) Quantitative summary of HEP and HPC analysis at days 10 and 15 of EB differentiation following stepwise treatment with Dox. Data represent the mean ± SD of 6 independent experiments.(C) Schematic of sorted HEP cell differentiation using OP9 coculture (upper panel). GATA2-induced HEPs showed a higher capacity to differentiate into CD34^+^/CD45^+^ and CD45^+^ hematopoietic cells (lower panel). Data represent the mean ± SD of 3 independent experiments.(D) Representative dot plots and bar graphs show cell-cycle analysis using EdU and DAPI staining on HEPs and HPCs treated or not with Dox. Data represent the mean ± SD of 3 independent experiments.(E) Apoptosis analysis in HEPs and HPCs in control and Dox-treated cells.Data represent the mean ± SD of 3 independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

To better understand the role of GATA2 in early hematopoiesis, we treated iGATA2-hiPSCs with Dox at distinct stages of EB development (days 2--7, 7--15, and 10--15). Induction of GATA2 at days 2--7 had the greatest effect on HEP and HPC generation ([Figure 2](#fig2){ref-type="fig"}B), while treatment at days 7--15 had no significant effects on the HEP population, and only a small effect was observed for early HPCs. By contrast, GATA2 overexpression at days 10--15 led to a significant decrease in HPC numbers ([Figure 2](#fig2){ref-type="fig"}B), consistent with previous findings showing that high GATA2 expression in HSCs blocks normal hematopoiesis ([@bib44], [@bib58]).

To address whether the higher hematopoietic output could be a consequence of a higher HEP generation, CD34^+^ cells were purified from day 10 EBs with or without Dox treatment, and were cultured on OP9 stromal cells ([@bib9], [@bib46]) ([Figure 2](#fig2){ref-type="fig"}C, upper panel). After 4 days of coculture, both CD34^+^CD45^+^ and total CD45^+^ cell subpopulations increased significantly in the cocultures derived from Dox-treated cells (∼3- and 4-fold, respectively), whereas the number of HEPs decreased slightly ([Figure 2](#fig2){ref-type="fig"}C, lower panel). To further characterize the effect of GATA2 during mesoderm patterning, we performed single-cell cloning assays of mesodermal cells (KDR^+^CD34^--^CD31^--^) using OP9 stromal cells and conditions that support hemato-endothelial differentiation. Dox treatment slightly increased the hematopoietic/endothelial ratio over control (no-Dox) ([Figure S2](#mmc1){ref-type="supplementary-material"}A, upper table). We repeated single-cell clonal analysis of CD31^+^CD34^+^CD43^--^ cells purified from day 7 EBs with or without Dox, finding that Dox-treated cells showed an increased number of hematopoietic colonies but a smaller proportion of endothelial growth ([Figure S2](#mmc1){ref-type="supplementary-material"}A, lower table), overall increasing the hematopoietic/endothelial ratio by \>4-fold.

Because GATA2 has been associated with adult HSC survival ([@bib58]), we questioned whether the increase in hematopoiesis was the consequence of GATA2-mediated proliferation/survival of emerging HEPs and HPCs. We analyzed apoptosis and cell-cycle distribution after GATA2 induction in HEPs and HPCs at days 10 and 15 of EB development, respectively, finding that GATA2 induction did not affect survival or proliferation of differentiating cells ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S2](#mmc1){ref-type="supplementary-material"}B).

Overall, our data are consistent with recent reports ([@bib28], [@bib68]) showing that, rather than induction of HEP specification or the selective proliferation/survival of HEPs/HPCs, GATA2 induces hematopoietic development by promoting EHT.

GATA2 Activates the Hematopoietic Program and Inhibits Cardiac Genes {#sec2.2}
--------------------------------------------------------------------

To gain mechanistic insight into how GATA2 promotes hematopoietic development, we performed RNA sequencing (RNA-seq) of fluorescence-activated cell sorting (FACS)-sorted control or GATA2-overexpressing HEPs from day 2 to 7 of differentiation. We used the criteria of \>1.5-fold change and adjusted p value \< 0.05 to identify differentially expressed genes (DEGs) in the two treatment groups.

Among 1,127 genes significantly deregulated by GATA2 induction, 700 were downregulated and 427 were upregulated ([Table S2](#mmc2){ref-type="supplementary-material"}). Consistent with the *in vitro* results, GATA2 activated a broad spectrum of genes regulating HSC/HPC development (e.g., *RUNX1*, *MYB*, *STAT1*, *ITGA2B/CD41*, *SPN/CD43*, *SPI1/PU.1*, *ZBT3*, and *ALDH1A1*), as well as of genes of myeloid (*CD33*, *CD53*, *CD48*, *CSFR1*, and *MPO*) and erythroid (*NFE2*, *GATA1*, *KLF1*, *HBZ*, *HBE1*, *HBA1*, and *HBG2*) lineages ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Proinflammatory cytokines have been proposed as positive regulators of definitive hematopoiesis in the mouse AGM region and its zebrafish equivalent ([@bib15], [@bib22], [@bib49]). In accord with this, gene ontology (GO) and gene set enrichment analysis showed that GATA2-overexpressing HEPs were highly enriched for genes associated with immune response (*IRF7*, *IFI27*, *IFIT1*, *TMEM173*, *IFI6*, *IFITM1*, *TRIM6*, *TRIM14*, and *TRIM25*) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Surprisingly, several highly significant GO categories of downregulated genes were related to heart development and cardiogenesis ([Figure S3](#mmc1){ref-type="supplementary-material"}B), including transcription factors such as *TBX3*, *MYOCD*, *PTX2*, *NR2F2*, and *FOXC2*, and structural genes including *TNNC1*, *RYR3*, *SPNS2*, *DVL3*, *SMO*, *NEBL*, *HEG1*, and *CCM2L* ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

Furthermore, expression of genes related to angiogenesis and endothelial cell differentiation (*JAG-1*, *KDR*, *SOX17*, *PCDH12*, *TEK*, *ESM1*, and *SCUBE1*) were also found to be downregulated ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These data strongly suggest that GATA2 has a dual activity during mesodermal patterning.

GATA2 Directly Binds Cardiac Genes {#sec2.3}
----------------------------------

To determine the direct effects of GATA2 on gene transcription, we performed ChIP-seq analysis for GATA2 occupancy on FACS-sorted GFP^+^ cells at day 7 of EB development, coinciding with the maximum expression of the GATA2 transgene ([Figure S1](#mmc1){ref-type="supplementary-material"}E). We identified 2,097 GATA2 binding-associated genes ([Figures 3](#fig3){ref-type="fig"}A, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). GATA2 was found to be enriched around the transcriptional start site of many genes harboring a GATA2 binding motif ([Figures 3](#fig3){ref-type="fig"}B--3D and [S3](#mmc1){ref-type="supplementary-material"}E), indicating that GATA2 does not occupy unscheduled genomic binding sites in iGATA2-hiPSCs. Integrated analysis with RNA-seq data indicated that only 8% of upregulated genes were decorated with GATA2 (35 genes in total), whereas up to 20% of downregulated genes were occupied by GATA2 (143) ([Figure 3](#fig3){ref-type="fig"}E). Probabilistic analysis indicated that GATA2 occupancy on repressed genes was significantly higher than would be expected by random chance (p \< 10^−16^), suggesting a predominant function of GATA2 repressing gene transcription during mesodermal lineage differentiation ([Figure 3](#fig3){ref-type="fig"}E). Among the upregulated GATA2 target genes, we identified determinants for hematopoietic development such as *RUNX1* and *NFE2* ([Figures 3](#fig3){ref-type="fig"}F and 3G). Of note, several of the downregulated GATA2 target genes were associated with heart development, such as *TBX3* and *PITX2* ([Figures 3](#fig3){ref-type="fig"}F and 3G), confirming the RNA-seq data.Figure 3Identification of GATA2 Target Genes during Mesoderm Specification(A) Venn diagram indicating the overlap between the number of genes found targeted by GATA2 in each replicate of the ChIP-seq of GATA2 in EBs (plus Dox).(B) MEME-ChIP motif analysis on the sequence of the GATA2 peaks in two independent ChIP-seq replicates showing an enrichment of GATA2 motifs at the center of the ChIP-seq peaks, as the top-ranked motif.(C) Genomic distribution of ChIP-seq peaks of GATA2 compared with the whole genome in two independent clones. The pie chart represents the distribution of GATA2 peaks corrected by the genome-wide distribution of each gene feature (background circle distribution). The pie chart indicates that GATA2 preferentially occupies TSS neighborhood regions, including 5′ UTR and PROXIMAL regions. The DISTAL region is the region within 2.5 and 0.5 kbp upstream of the TSS. The PROXIMAL region is the region within 0.5 kbp of the TSS. CDS is the protein CoDing Sequence. INTRONS are intronic regions. INTERGENIC is the remainder of the genome. TSS is the transcription start site.(D) Meta-gene plot showing the GATA2 ChIP-seq profile occupancy in iPSCs (CL6 no-Dox) and EBs (CL6 plus Dox) and IgG from −5 kb of the TSS until +5 kb of transcription end site (TES).(E) Histogram of the proportion of GATA2 target genes deregulated after induction of GATA (iGATA2) (up or down, 1.5-fold change, false discovery rate \< 0.05) during EB development (p value was calculated using chi-square test).(F) Functional analysis on the mammalian phenotype enrichment ontology for the deregulated GATA2 target genes (MGI database).(G) UCSC genome browser screenshots of several developmental hematopoietic and cardiac genes targeted by GATA2.(H) Relative luciferase activity of COS7 cells transfected with reporter plasmids for *ISL1* (−1,960/+369), *PITX2* (−4,350/−3,192), or *TBX3* 3′ UTR genes and pWPI-GATA2 plasmid. Relative luciferase activity is shown as the ratio of luciferase activity to that in cells cotransfected with mock vector.A representative result of three independent experiments performed in triplicate is shown as the mean ± SD. Differences were determined using Student\'s t test; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

The specific binding of GATA2 to proximal gene regions of cardiac regulators strongly suggests that GATA2 directly controls the repression of genes involved in cardiac development. To test this, we used a luciferase reporter assay in COS7 cells for three cardiac genes (*TBX3*, *PITX2*, and *ISL-1*), according to the ChIP-seq data. Luciferase activity driven by the 3′ UTR of the *TBX3* promoter, the −1,960/+369 region of the *ISL-1* promoter, and the −4,350/−3,192 region of the *PITX2* promoter, was significantly reduced by GATA2 coexpression ([Figure 3](#fig3){ref-type="fig"}H). Thus, in addition to validating GATA2 as a pro-hematopoietic fate regulator, these data point to an additional and undescribed role for GATA2 in repressing cardiac regulation.

Single-Cell RNA-Seq of Mesodermal and Hemato-Endothelial Progenitors {#sec2.4}
--------------------------------------------------------------------

To better characterize the effect of GATA2 overexpression on mesodermal diversification, we performed single-cell RNA-seq (scRNA-seq) on FACS-purified mesodermal (KDR^+^CD34^--^CD31^--^; EBs d5) and hemato-endothelial progenitor (KDR^+^CD34^+^CD43^--^; EBs d7) cells with or without Dox ([Figure S4](#mmc1){ref-type="supplementary-material"}A). EB-derived cells from day 2 were profiled as the starting population.

In unsupervised clustering based on the Seurat method ([@bib5]), we identified five transcriptionally distinct cell clusters ([Figure 4](#fig4){ref-type="fig"}A). The t-distributed stochastic neighbor embedding (t-SNE) projection visualized that day 2 EB-derived cells formed one expression signature cluster, whereas mesodermal (day 5) and hemato-endothelial (day 7) cells showed the presence of two subpopulations in each cluster ([Figure 4](#fig4){ref-type="fig"}B). We assigned biological identities to each cluster based on the expression of key marker genes (adjusted p value \< 0.05) ([Table S3](#mmc3){ref-type="supplementary-material"}). Cluster 1 (EBs day 2) showed high expression of pluripotency genes (*NANOG*, *OCT4/POU5f1*, *ZFP42/REX1*, *DPPA4*, and *SALL2*), indicating maintenance of undifferentiated pluripotent cells. Cluster 2 (mesodermal S1) showed a multi-lineage mesodermal identity (*BMP4*, *MSX2*, *PDGFRA*, *LGR5*, *CDX2*, *FRZB*, *HOXA1*, *BMP5*, *FTH1*, *WNT5A*, *WNT5B*, *HAND1*, *TNNT1*, and *TBX3*). Cluster 3 (mesodermal S2) lacked expression of mesodermal markers, but co-expressed *ETV2*, its target SCL/*TAL1*, and *EGFL7*, which are responsible for restricting mesoderm specification to endothelium fate ([@bib63]), and genes suggestive of a mesenchymal phenotype (*COL1A1*, *COL6A3*, *COL3A1*, *COL6A2*, *ACTA2*, and *LUM*). Cluster 4 (hemato-endothelial S1) and cluster 5 (hemato-endothelial S2) shared the expression of several key hemato-endothelial markers (*CDH5*, *PECAM1*, *ICAM2*, *CD40*, *ESAM*, *FLI1*, *ERG*, *ETS1*, and *HHEX*); however, hemato-endothelial S2 cells showed a more restrictive endothelial identity (expressing selectively *NOTCH4*, *SOX7*, *NRP2*, *TEK*, and *NOS3*). Also, we noted that hemato-endothelial S1 was enriched for genes that regulate cell cycle (*AURKB*, *TOP2A*, *CDK1*, *MKI67*, *BRCA2*, *CASC5*, and *CDCA5*).Figure 4Single-Cell RNA-Seq Analysis Reveals GATA2 as a Driver of Hemato-Endothelial Specification(A) Heatmap showing the expression pattern of top 10 gene markers distinguishing 5 clusters from scRNA-seq analysis. Colored top bar indicates assigned cluster. Red indicates the highest scaled expression and blue the lowest.(B) t-SNE visualization plot of day 2 (d2) EBs, mesodermal d5 and hemato-endothelial d7 cells according to clusters in (A).(C) t-SNE visualization plot of single cells of each cluster retrospectively colored by Dox (red) and no-Dox treatment (gray).(D) Stacked bar diagram showing the percentage of cells in each cluster with respect to treatment conditions.

Next, we retrospectively colored each cluster on the basis of Dox and no-Dox conditions ([Figure 4](#fig4){ref-type="fig"}C). For each cluster, the number of cells per condition was calculated and each Dox condition was compared with that of the corresponding no-Dox condition ([Table S3](#mmc3){ref-type="supplementary-material"}). A chi-square test showed that treatment and cluster populations were not independent (p = 0.0002687). Considering an adjusted p value \< 0.05, the *post hoc* comparisons showed that, at day 5 of EB development, the proportion of mesodermal S1 cells increased significantly in Dox conditions (chi-square = 6.816191, adjusted p value = 0.018067005) ([Figure 4](#fig4){ref-type="fig"}D). At day 7, GATA2 overexpression induced an enrichment of the hemato-endothelial S1 cluster (chi-square = 3.082502, adjusted p value = 0.079138704) ([Figure 4](#fig4){ref-type="fig"}D).

Based on these data, we speculate that GATA2 enhances the proportion of cells with a multi-lineage mesodermal signature and further increases the probability, at the single-cell level, that a mesodermal progenitor acquired a hemato-endothelial transcriptional profile. These data are consistent with our FACS analysis ([Figure S4](#mmc1){ref-type="supplementary-material"}A) and are in line with recent findings showing that GATA2 overexpression enhances the generation of mesodermal cells and further promotes EHT ([@bib68]).

Finally, we performed a new clustering analysis of mesodermal (day 5) and hemato-endothelial single cells (day 7) based on DEGs (1,127 genes) identified in our bulk RNA-seq analysis (HEPs day 10) ([Table S4](#mmc4){ref-type="supplementary-material"}). Using t-SNE and hierarchical clustering to visualize the data, five main clusters were found ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). GO enrichment analysis and over-representation analysis ([@bib2]) revealed that cluster 0 and cluster 4 were associated with hemato-endothelial progenitors (*ESCR*, *CDH5*, *ERG*, *SOX17*, and *HOXA9*), cluster 3 mesoderm (*TBX3* and *MSX1*), cluster 1 mesenchymal (*FN1*, *LAMA1*, and *COL5A1*), and cluster 2 epiblast (*EPCAM* and *CDH1*) ([Figure S4](#mmc1){ref-type="supplementary-material"}D). These data are in line with the scRNA-seq analysis and suggest that most of the DEGs (1,056 genes) of day 10 were already differentially expressed in our single cells at d5 and d7.

GATA2 Knockout Inhibits Hematopoietic Development and Favors Cardiomyogenesis {#sec2.5}
-----------------------------------------------------------------------------

Our results so far strongly suggest that transient GATA2 expression promotes hematopoietic differentiation and represses alternative mesodermal fates during HEP specification. To address whether GATA2 is necessary for specification of HEPs, we used CRISPR/Cas9 gene editing to target exon 2 of *GATA2* and generate knockout hiPSC-GATA2 clones (hiPSC-GATA2^KO^). After expanding individual clones, we selected two targeted clones with biallelic mutations (CL14 and CL19; [Figure 5](#fig5){ref-type="fig"}A). Immunocytochemistry and qRT-PCR analysis confirmed the absence of GATA2 expression during hiPSC-GATA2^KO^ differentiation ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). No predicted CRISPR off-targets were detected by genomic sequencing of hiPSC-GATA2^KO^ clones ([Figure S5](#mmc1){ref-type="supplementary-material"}C). The hiPSC-GATA2^KO^ clones retained a normal karyotype and maintained the expression of pluripotency markers ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E), confirming that the *GATA2* knockout is compatible with human stem cell pluripotency.Figure 5GATA2 Is Essential for HPC Development(A) Representative sequencing of targeted homozygous hiPSC clones at the *GATA2* locus using sgRNA1 and sgRNA2; PAM sequences are labeled in yellow.(B) Quantitative summary of HEP and HPC FACS analysis at d10 and d15 of EB development in wild-type (WT) and hiPSC-GATA2^KO^ clones. Data represent the mean ± SD fold change relative to *WT* iPSC lines.(C) qRT-PCR analysis of hematopoietic and cardiac regulators in WT and hiPSC-GATA^KO^ clones during EB development.Data represent the mean ± SD of 3 independent experiments. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

We differentiated wild-type and hiPSC-GATA2^KO^ clones into hematopoietic cells as described earlier (see [Figure 1](#fig1){ref-type="fig"}A). As expected, *GATA2* knockout significantly affected HEP generation (CD31^+^CD34^+^CD45^--^) in day 10 EBs ([Figure 5](#fig5){ref-type="fig"}B) and markedly decreased the number of HPCs (CD34^+^CD43^+^CD45^+^) in day 15 EBs ([Figure 5](#fig5){ref-type="fig"}B). Moreover, we consistently failed to detect hematopoietic CFCs at day 10 of EB development (data not shown).

In line with the transcription and ChIP-seq data, qRT-PCR analysis revealed that the cardiac regulators *TBX3*, *NKX2.5*, and *MYOCD* were progressively upregulated during hiPSC-GATA2^KO^ EB development, whereas the hematopoietic transcription factors *SCL*, *GATA1*, and *PU.1* were markedly suppressed ([Figure 5](#fig5){ref-type="fig"}C).

As these observations strongly suggest that interfering with *GATA2* expression might be an effective strategy to generate cardiomyocytes *ex vivo*, we differentiated hiPSC-GATA2^KO^ and iGATA2-hiPSC lines (with or without Dox administration, days 2--7) to cardiomyocytes using a well-characterized protocol ([@bib33]) ([Figure 6](#fig6){ref-type="fig"}A), and measured the expression of the cardiac structural proteins troponin I (cTnI) and myosin heavy chain (MHC) after 20 days. Remarkably, we found a ∼3-fold increase in the number of cTnI^+^ MHC^+^ cells in differentiated hiPSC-GATA2^KO^ cells compared with iGATA2-iPSC cells in the absence of Dox ([Figures 6](#fig6){ref-type="fig"}B and 6C). Conversely, Dox administration led to a significant decrease in the number of cTnI^+^ MHC^+^ cells in the iGATA2-iPSC line ([Figures 6](#fig6){ref-type="fig"}B and 6C). As a functional readout of cardiomyocyte generation, we monitored for the appearance of beating cells. Whereas the majority of hiPSC-GATA2^KO^ cells started beating at days 8--10 of differentiation and persisted throughout the 20-day experiment ([Videos S1](#mmc5){ref-type="supplementary-material"} and [S2](#mmc6){ref-type="supplementary-material"}), very few iGATA2-iPSC cells treated with Dox were beating ([Video S3](#mmc7){ref-type="supplementary-material"}). Taken together, these results suggest that GATA2 is both an activator of hematopoiesis and a repressor of cardiac cell fate.Figure 6GATA2 Knockout Promotes Cardiomyocyte Differentiation(A) Schematic of the cardiomyocyte differentiation protocol.(B) Representative FACS analysis of the percentage of cTnI^+^ MHC^+^ cells in hiPSC-GATA2^KO^ and iGATA2-iPSC lines (with and without Dox treatment) at day 20 of differentiation.(C) Bar graph showing the mean percentage of cTnI^+^ MHC^+^ cells in (B). Data represent the mean ± SD of 3 independent experiments. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.

Video S1. hiPSC-GATA2^KO^ CL14 Cardiomyocytes

Video S2. hiPSC-GATA2^KO^ CL19 Cardiomyocytes

Video S3. hiGATA2-iPSC Cardiomyocytes Dox Treated

Discussion {#sec3}
==========

GATA2 has long been implicated as a master regulator of murine hematopoiesis ([@bib59], [@bib60]), and its dysregulation is associated with human immunodeficiency syndromes ([@bib54]). However, its role in early human hematopoiesis is less clear. Human iPSCs are a useful model to interrogate the molecular mechanisms driving early hematopoietic development.

To our knowledge, this is the first study showing a dual activity of GATA2 in human early hematopoiesis. We show that GATA2 drives mesoderm progenitors to differentiate into blood cells and represses cardiac fates. Indeed, our *GATA2* knockout model confirmed that loss of GATA2 activity impairs hematopoietic development and enhances cardiomyocyte differentiation.

Earlier studies both *in vivo* and in stem cell models suggested that hematopoietic and cardiac lineages develop in close proximity and are mutually antagonistic ([@bib4], [@bib7], [@bib8], [@bib16], [@bib30], [@bib36], [@bib50], [@bib61]). For example, overexpression of *Scl* in mesodermal cells promotes hematopoietic development at the expense of cardiomyogenesis in differentiated mouse ESCs ([@bib24]), whereas *Scl*-deficient mice show ectopic cardiomyocytes in yolk salc endothelium and die at E9.5 due to the complete absence of hematopoiesis ([@bib53], [@bib61]). Similarly, *Etv2/Er71* deficiency leads to a complete block of hemato-endothelial development and a concomitant expansion of the cardiac lineage in mutant embryos ([@bib31], [@bib32], [@bib37], [@bib47]), whereas *Etv2* overexpression in differentiating mouse ESCs shows the opposite phenotype ([@bib37]).

To date, a direct role for GATA2 in cardiac development has not been demonstrated. *Gata2*-null mice have no apparent cardiovascular phenotype, but to our knowledge studies specifically addressing heart malformation in *Gata2* mutants have not been performed. Whether GATA2 overexpression *in vivo* enhances hematopoietic cell specification while concurrently retarding cardiac development should be addressed in the future.

GATA2 is known to cooperate with ER71/ETV2 and SCL/TAL1 to regulate endothelial and hematopoietic programs in stem cells ([@bib14], [@bib52]). The recent observation that coexpression of ER71/ETV2, SCL/TAL1, and GATA2 during mouse ESC differentiation enhances FLK-1^+^ hemangioblast production while blocking cardiac output ([@bib36]) suggests a critical regulatory relationship between these factors during mesoderm diversification. Nevertheless, the gene regulatory network governing hematopoietic and cardiac development is poorly understood. Our bulk RNA-seq data revealed that GATA2 overexpression failed to upregulate ER71/ETV2 expression in our HEP model, which is consistent with the finding that ER71 is expressed before GATA2 during both early mouse and ESC development ([@bib36]). Based on recent studies ([@bib7], [@bib42]), it is reasonable to presume that GATA2 and SCL collaborate to promote blood specification at the expense of cardiac fates. Yet, our deep DNA motif enrichment analysis of GATA2 targets demonstrate the absence of SCL binding sites (CANNTG) in both GATA2-bound activated and repressed genes, which suggests that these two factors---at least in our experimental model---act independently. Of note, recent analysis at the single-cell level revealed that only a subset of mouse E8.5 *Scl*^−/−^ endothelial cells upregulated expression of a few cardiac-related genes. However, those cells did not display a full cardiomyocyte transcriptional program and continued to express key endothelial markers ([@bib45], [@bib51]). Therefore, the role of SCL in the specification of hematopoietic fate and as a cadiac repressor needs to be determined.

ChIP-seq indicated that GATA2 acts more as a repressor than an activator during mesodermal diversification. Specifically, GATA2 binds directly to cardiac regulator promoters, leading to their downregulation. Although previous studies in HPCs and mature blood cells have shown that endogenous GATA2 preferentially occupies sites distant to promoters ([@bib6], [@bib17], [@bib23], [@bib65]), our analysis revealed GATA2 binding promoter regions. Whether this apparent discrepancy is a consequence of cell-type-specific differences in GATA2 occupancy, the fact that GATA2 is overexpressed in our studies, or both, is unclear.

Enforced expression of instructive factors is an accepted strategy to guide lineage fate commitment ([@bib12], [@bib14], [@bib40], [@bib41], [@bib46], [@bib56]), and offers the possibility to generate any differentiated cell type from hPSCs. Our study provides cellular and molecular evidence that GATA2 induction promotes an enhancement of mesodermal cells with hemato-endothelial potential, and decreases the probability that alternative mesodermal fates occur. Accordingly, GATA2 could be a target for manipulation to improve the yield of target cells (blood or cardiomyocytes) from hPSCs for drug screening and disease modeling.

In summary, we establish a novel role for GATA2 during mesodermal lineage specification and provide new insights into the complex regulatory network that controls human early hematopoietic development.

Experimental Procedures {#sec4}
=======================

Human iPSC Culture {#sec4.1}
------------------

Human GATA2-hiPSC and iPSC-GATA2^KO^ lines were maintained on Matrigel-coated 60-mm plates in mTESR1 medium ([@bib19]). Culture medium was changed daily and cells were passaged weekly by EDTA dissociation.

EB-Based Hematopoietic Differentiation {#sec4.2}
--------------------------------------

Human iPSCs were differentiated as described ([@bib19]). In brief, EBs were treated with the GSK3 inhibitor CHIR99021 (3 μM) from day 2 to 3 of culture ([@bib55]). From day 3, EBs were cultured in differentiation medium until day 15. To induce transgene GATA2 expression Dox (1 μg/mL) was added from day 2 to 7 of differentiation.

Cardiac Differentiation {#sec4.3}
-----------------------

Human iPSCs were differentiated in monolayer cultures with modulators of canonical Wnt signaling ([@bib33]). Contracting cardiomyocytes could be observed between day 8 and 10 of differentiation. Differentiated cells were disaggregated at day 20 with 0.25% trypsin-EDTA for 5--8 min at 37°C for FACS analysis.

ChIP-Seq Combined with DNA Massive Sequencing {#sec4.4}
---------------------------------------------

GATA2-iPSCs (CL6 and CL9) were differentiated in the presence of Dox (from day 2 to 7). ChIP experiments were performed with ∼1.5 × 10^6^ cells using the ChIP-IT High Sensitivity Kit from Active Motif (no. 53040), and specific antibodies for GATA2 (Santa Cruz; sc-9008) or rabbit IgG as isotype control (Abcam; 172730), Libraries were prepared according to Illumina instructions and sequenced using the HiSeq 2000 platform (Illumina).

Statistical Analysis {#sec4.5}
--------------------

All data are expressed as mean ± SD. Statistical comparisons were performed using Student\'s t test (95% confidence interval). Statistical significance was defined as p \< 0.05.
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